Navigation Links
Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
Date:12/12/2011

r response with Tasigna for people living with this cancer."

CML is responsible for approximately 10% to 15% of all adult cases of leukemia in the US, with an incidence of one to two cases per 100,000 people per year(6,7).

ENESTcmr study detailsENESTcmr is an open-label, randomized, prospective, multi-center Phase III study of Tasigna 400 mg twice daily versus standard-dose Gleevec (400 mg or 600 mg once daily) comparing kinetics of CMR for patients with Ph+ CML in chronic phase who had achieved complete cytogenetic response (CCyR) but were still Bcr-Abl positive (i.e., had evidence of residual leukemia) after at least two years of treatment with Gleevec. The study enrolled 207 patients. The patients were randomized into one of two treatment arms: Tasigna 400 mg twice daily versus continuing Gleevec 400 mg or 600 mg once daily (same dose as at study entry)(1).

The primary endpoint was the rate of confirmed best cumulative CMR by 12 months of study therapy with Tasigna or Gleevec. Samples with any detectable level were considered not to be in CMR. The lowest detected Bcr-Abl value was 0.00073%. Secondary objectives included the kinetics of CMR, duration of CMR, progression-free survival and overall survival in both arms. CMR was defined at three levels: CMR (CMR greater than or equal to 4.5-log, undetectable Bcr-Abl by RQ-PCR at a sensitivity of less than 0.0032%), CMR4 (CMR greater than or equal to 4-log, undetectable Bcr-Abl by RQ-PCR at a sensitivity of 0.01% or less) and CMR4.5 (CMR greater than or equal to 4.5-log, undetectable Bcr-Abl by RQ-PCR at a sensitivity of 0.0032% or less)(1).

These data showed that 23% of patients taking Tasigna achieved undetectable disease (24 patients) by 12 months, compared to 11% (11 patients) taking Gleevec(1).

A majority of patients in both treatment arms received prior Gleevec treatment for at least three years before entering the trial. Patients randomized to receive Ta
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... ALBANY, New York , August 27, 2014 /PRNewswire/ ... on United States  Laparoscopes Market Outlook ... to 2020", provides key market data on the ... in millions of US dollars, volume (in units) and ... Laparoscopes (Rigid Tip Video Laparoscopes and Flexible Tip Video ...
(Date:8/27/2014)... -- Reportlinker.com announces that a new market research report ... Eastern Europe 2014 http://www.reportlinker.com/p02312454/Baby-Food-Eastern-Europe-2014.html ... a new report by ERC that analyzes the Baby ... , key segments, features & developments, future projections ... which are currently affecting the industry. Furthermore, it profiles ...
(Date:8/27/2014)... 2014 Sihuan Pharmaceutical Holdings Group Ltd. ... leading pharmaceutical company with the largest cardio-cerebral vascular ... prescription drug market, today announced the unaudited ... (collectively the "Group") for the six months ended ... HighlightsFor the Six months ended 30 JuneKey Income ...
Breaking Medicine Technology:United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 2United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 3United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 4United States Laparoscopes Market Outlook, Analysis, Size, Share, Growth, Trends And Forecast 2020 5Baby Food Eastern Europe 2014 2Baby Food Eastern Europe 2014 3Baby Food Eastern Europe 2014 4Baby Food Eastern Europe 2014 5Baby Food Eastern Europe 2014 6Baby Food Eastern Europe 2014 7Baby Food Eastern Europe 2014 8Sihuan Pharmaceutical Announces 2014 Interim Results 2Sihuan Pharmaceutical Announces 2014 Interim Results 3Sihuan Pharmaceutical Announces 2014 Interim Results 4Sihuan Pharmaceutical Announces 2014 Interim Results 5Sihuan Pharmaceutical Announces 2014 Interim Results 6Sihuan Pharmaceutical Announces 2014 Interim Results 7
... Dendreon Corporation (Nasdaq: DNDN ) today announced ... Healthcare Conference in San Francisco on January 10, 2011 at ... audio webcast live and available for replay from Dendreon,s website, ... the live webcast, it will be archived on the site ...
... PDL BioPharma, Inc. (PDL) (Nasdaq: ... president and chief executive officer, is scheduled to present at ... at 7:30 a.m. Pacific time. This presentation will ... audio webcast. To access the live and subsequently archived webcast ...
Cached Medicine Technology:
(Date:8/28/2014)... AMTC graduate, rising star and The Voice Season ... the Top 10 finalists for Pepsi’s Southern Original . He’s ... for his mentor and coach from The Voice and country music ... slot on Thursday, August 28th at 9:00 pm at Tootsie’s at ... will perform at the Gulf Coast Jam main stage on Sunday, ...
(Date:8/28/2014)... NC (PRWEB) August 28, 2014 ... 24-26, 2014 in Asheville, NC at holistic retreat ... ChiRunning & ChiWalking founders, Katherine and Danny Dreyer, ... ability to learn techniques that support a lifetime ... setting. , Nestled in the heart of ...
(Date:8/28/2014)... MMAR Medical is pleased to announce ... for regular customers to enjoy several perks and benefits ... a wholesale license. It’s a great choice for independent ... others who regularly purchase medical braces but could use ... own active lifestyle or those of your club, group ...
(Date:8/28/2014)... Worth, Texas (PRWEB) August 28, 2014 The ... significant growth over the past few years. The new location ... will offer higher quality and larger office space than TLC ... growth. , “We are pleased about our new location ... said. “While our suite will be double in size compared ...
(Date:8/27/2014)... NC (PRWEB) August 28, 2014 ... companies to acquire as part of a strategic ... Aeroflow is positioned for taking ownership of new ... to increase economies of scale. , Last week, ... agreement with Hometown Respiratory to increase service in ...
Breaking Medicine News(10 mins):Health News:Rising Star Brandon Chase Named Finalist in Pepsi Southern Original Contest 2Health News:Join ChiRunning® & ChiWalking® Creators, Katherine and Danny Dreyer, for First-ever ChiWeekend Retreat in Asheville, NC 2Health News:Join ChiRunning® & ChiWalking® Creators, Katherine and Danny Dreyer, for First-ever ChiWeekend Retreat in Asheville, NC 3Health News:MMAR Medical Announces Customer Membership Program 2Health News:Aeroflow Healthcare Seeks Strategic Acquisition Opportunities 2
... environment caused mice to develop disease, study finds , THURSDAY, ... scientists have found a bacteria living in the gut may ... , The gut of all mammals is populated with thousands ... for developing a normal immune system. But some of these ...
... Announcing a new ... how to improve the look and strength of your abdominal muscles and improve overall health. ... Web site. , ... -- A new Web site has been developed to help anyone get in shape. If ...
... ... Safier, MD, Allergist/Immunologist, who will join ENTA in Bayside, NY effective August 1st. , ... Tarrytown, NY (Vocus) June 17, 2010 ... of Brian Safier, MD, Allergist/Immunologist, who will join ENTA in Bayside, NY effective August 1st. ...
... ... Pfizer, Merck, Medtronic, GTx, Johnson & Johnson, and the University of Virginia School of Medicine. ... Charlottesville, VA, San Francisco, ... focus on regulatory compliance in the life sciences, openQ has formed a Compliance Advisory Board. ...
... there are now new areas in which whole body magnetic ... of Deutsches rzteblatt International ( Dtsch Arztebl Int ... a review of possible uses, together with the limits of ... suitable for routine use in hospitals, as the procedure takes ...
... myofibroblastic tumor (IMT) is an uncommon benign neoplasm with locally ... tumor occurring in a 14-year-old patient with clinical presentations of ... A research article to be published on June ... addresses this question. A research team led by Professor Ko ...
Cached Medicine News:Health News: Stomach Bacteria Might Trigger Rheumatoid Arthritis 2Health News: Stomach Bacteria Might Trigger Rheumatoid Arthritis 3Health News:New Web Site Provides Helpful Exercise and Nutrition Tips 2Health News:ENT and Allergy Associates Continues to Bolster Bayside Presence and Expertise, Adds Allergist/Immunologist Dr. Brian Safier, 2Health News:ENT and Allergy Associates Continues to Bolster Bayside Presence and Expertise, Adds Allergist/Immunologist Dr. Brian Safier, 3Health News:openQ Announces the Formation of a Compliance Advisory Board 2Health News:openQ Announces the Formation of a Compliance Advisory Board 3
Used in conjunction with the E5381 700 Circling Band (240 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Massive retinal breaks. Inner diameter: 26 mm....
2 mm x 0.75 mm. Overall length: 125 mm, 4.9 inches....
...
Medicine Products: